Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Kiora Pharmaceuticals in-licenses late-stage oral calpain inhibitor KIO-401 from Senju Pharmaceutical for CRAO, NAION
Licensing deal, rare disease, small molecule, ophthalmology, milestone payments - Read more

Setara Biosciences launches with $90M financing to develop Charcot-Marie-Tooth and rare disease treatments
Rare disease, small molecule, neurological, ion channel, clinical-stage - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Regeneron reports "clean sweep" Q3 with $5.1B revenue, 36% growth; key pipeline catalysts ahead
Monoclonal antibody, oncology, autoimmune, financial, revenue impact - Read more

AbbVie beats Q3 estimates, raises full-year guidance, eyes bolt-on acquisitions over megadeals
Small molecule, autoimmune, neurological, financial, strategic - Read more

Gilead Sciences' Q3 HIV sales surge 18% to $6.2B, driving highest annual growth since 2015
Small molecule, HIV, revenue impact, financial - Read more

Bambusa Therapeutics prices upsized $168.9M IPO, developing bispecific antibodies for immunology
Clinical-stage, bispecific antibody, immunology, inflammation, long-acting - Read more

Aspen Neuroscience raises $140.6M IPO to advance Parkinson's personalized cell therapy
Cell therapy, Parkinson's disease, neurological, stem cell, clinical-stage - Read more

Bracco invests $230M to build first U.S. diagnostic imaging manufacturing facility in North Carolina
Contrast media, diagnostic imaging, operational, major transaction - Read more

Roche globally launches VENTANA BAP1 IHC test for mesothelioma differential diagnosis
Immunohistochemistry, mesothelioma, rare disease, oncology, regulatory - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Acumen Pharmaceuticals' (sabirnetug) Ph2 fails to improve cognition in early Alzheimer's disease, prompting development discontinuation
Antibody, neurological, monoclonal antibody, Alzheimer's disease, amyloid beta, blood-brain barrier - Read more

Gilead places partial clinical hold on KITE-753 (anti-CD19/CD20) Ph2/Ph3 trials in diffuse large B-cell lymphoma over safety concerns
Cell therapy, cancer, CAR-T, diffuse large B-cell lymphoma, CD19/CD20 target, ICANS - Read more

Eli Lilly drops (mevidalen) Ph2 program for symptomatic Alzheimer's disease after failing internal success bar
Small molecule, neurological, dopamine D1 receptor modulator, Alzheimer's disease, positive allosteric modulator - Read more

Alnylam CEO admits franchise underperformance as stock plunges 56% amid mounting competitive and pricing pressures
RNA interference, rare disease, financial, competitive, regulatory - Read more

Lenz Therapeutics cuts 75% of workforce, replaces CEO amid commercial struggles with Vizz eye drops
Small molecule, ophthalmology, cost reduction, operational - Read more

Molecular Partners to lay off up to 44% of workforce, pivoting focus to radiotherapeutic pipeline
Radiopharmaceutical, oncology, cost reduction, operational - Read more

AstraZeneca discontinues Ph1/2 AZD9750 androgen receptor degrader and AZD8359 STEAP2 T-cell engager for prostate cancer
Small molecule, cancer, prostate cancer, androgen receptor degrader, T-cell engager, STEAP2 - Read more

Sanofi targets late-stage and commercial M&A deals to offset looming Dupixent patent expiry in 2031
Monoclonal antibody, autoimmune, strategic, major transaction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here